# Retatrutide Dosage in the Research Literature | Doctor Retatrutide > Retatrutide dosage data from Phase 2 trials: 2 mg to 12 mg weekly titration protocol, dose-dependent weight loss (8.7% to 24.2% at 48 weeks), half-life, and pharmacokinetics. ## Retatrutide Dosage Overview Retatrutide dosage data comes from Lilly-sponsored Phase 1b, Phase 2, and Phase 3 clinical trials. Retatrutide is not FDA approved; the doses described here were administered to research participants in controlled clinical settings under protocol-specified titration schedules. All dosage information on this page is a summary of published trial data, not clinical guidance. ## Phase 2 Dose Escalation: 2 mg to 12 mg Findings The Phase 2 obesity trial (NEJM 2023, n=338) used a gradual dose escalation protocol starting at 2 mg, with participants escalating to their target dose to reduce gastrointestinal adverse event burden [1]. The target doses were 1 mg, 4 mg, 8 mg, or 12 mg once weekly, delivered subcutaneously. Weight loss at 48 weeks was dose-dependent: - 1 mg: 8.7% mean reduction - 4 mg: 17.1% mean reduction - 8 mg: 22.8% mean reduction - 12 mg: 24.2% mean reduction - Placebo: 2.1% reduction The Phase 2 type 2 diabetes trial (Lancet 2023, n=281) used doses from 1 mg to 12 mg once weekly over 36 weeks with a similar escalation structure [3]. At 8 mg, 82% of participants reached target HbA1c at or below 6.5%. At the highest doses, gastrointestinal adverse events — primarily nausea, vomiting, and diarrhea — were the primary dose-limiting factors. The dose escalation protocol was the trial's primary mitigation strategy for this burden. ## Dose-Dependent Weight Loss Outcomes in Retatrutide Trials The dose-response relationship in retatrutide Phase 2 data is among the most linear reported for any obesity pharmacotherapy. A pooled meta-analysis of three RCTs confirmed that the effect sizes were consistent and reproducible across different trial populations [6, 7]. The meta-analysis (Abouelmagd et al., 2025) found that pooled retatrutide treatment reduced body weight by a weighted mean difference of 10.66 kg versus placebo, with waist circumference reduced by 6.61 cm [6]. Risk ratios for weight loss thresholds: 2.92 for 5% or more, 9.32 for 10% or more, 18.40 for 15% or more, and 16.61 for 20% or more — all statistically significant [7]. At the body composition level, retatrutide 8 mg produced a 26.1% reduction in total body fat versus 4.5% in the placebo group at 36 weeks in the type 2 diabetes body composition substudy [8]. Lean mass loss was proportionally similar to other approved obesity pharmacotherapies — no disproportionate lean tissue depletion was identified by dual-energy X-ray absorptiometry. ## Retatrutide Half-Life and Pharmacokinetics Retatrutide has an approximately 6-day half-life in humans, confirmed in the Phase 1b multiple-ascending dose trial (Lancet 2022) [2]. Steady-state plasma concentrations are reached by approximately 4 weeks after initiation of weekly dosing. Peak plasma concentration (Cmax) is achieved within 12–72 hours after subcutaneous injection, reflecting the characteristic absorption and albumin-binding kinetics of lipidated peptides [15]. The fatty diacid moiety conjugated to the peptide backbone enables albumin binding, which protects the molecule from rapid enzymatic degradation and produces the extended half-life that makes once-weekly dosing pharmacologically viable. No cytochrome P450 drug-drug interactions were identified in preclinical and Phase 1 pharmacokinetic studies, reflecting that peptide drugs are metabolized through proteolysis rather than the hepatic CYP450 system [15]. The pharmacokinetic profile was described as dose-proportional in Phase 1b data across the 3 mg to 12 mg dose range studied. ## How Long Does Retatrutide Take to Work? Appetite suppression effects from retatrutide were reported as noticeable within the first 1–2 weeks in Phase 2 trial participants, reflecting the early satiation signals from GLP-1R and GIPR activation at even sub-steady-state plasma concentrations [10]. Meaningful weight changes — defined as 5% or more reduction — were observed in most Phase 2 trial participants by weeks 8–12, coinciding with dose escalation to therapeutic target levels and the approach toward steady-state plasma concentrations [2, 10]. The eating behavior data from the type 2 diabetes Phase 2 study showed that self-reported hunger scores began declining within the first four weeks, with disinhibited eating (a behavioral predictor of weight regain) also reduced by week 12 at doses of 4 mg and above [10]. ## What Happens When You Stop Taking Retatrutide? Weight regain after discontinuation is expected, based on both preclinical retatrutide data and the well-documented class biology of GLP-1 receptor agonists [17]. Upon retatrutide withdrawal in preclinical models, body weight rebounded and food intake elevated toward pre-treatment levels [17]. Clinical GLP-1 class discontinuation trials demonstrate that weight regain and attenuation of cardiometabolic benefit occur within 52 weeks of stopping treatment — with fat mass returning faster than lean mass. A 2026 review classified post-discontinuation weight regain as disease recurrence rather than treatment failure, reflecting the current scientific consensus that obesity is a chronic disease requiring long-term pharmacological management [17]. Retatrutide Phase 3 extension cohort data on post-discontinuation trajectories are not yet published. ## Route of Administration and Clinical Trial Protocol All clinical trials of retatrutide have administered the compound via subcutaneous injection once weekly [1, 2, 3]. No oral or intravenous formulations appear in the published literature as of mid-2026. The Phase 2 obesity trial protocol (NCT04881760) specified dose escalation starting at 2 mg with step-up increments at regular intervals to reach the randomized target dose [1]. This titration approach is consistent with other GLP-1 class agents where rapid dose escalation increases gastrointestinal adverse event rates. Steady-state exposure is reached approximately 4 weeks after the first injection at any given maintenance dose [15]. The [dose escalation protocol](/dosage#dose-escalation) detail above covers the specific Phase 2 dose arms and their 48-week outcomes. The [retatrutide half-life and pharmacokinetics](/dosage#half-life) section above provides the mechanistic context for the once-weekly schedule. --- A cinematic index of the Phase 2 and Phase 3 retatrutide trial record — primary sources only, no clinic, no prescription.